Clinical Trial Update: Surgicel® Fibrillar for Delayed Bleeding After ESD [NA]

View source ↗

Summary

A completed clinical trial evaluating Surgicel Fibrillar to prevent delayed bleeding after endoscopic submucosal dissection in patients with stomach neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Stomach Neoplasms

Drugs mentioned

• Surgicel Fibrillar (oxidized regenerated cellulose)

Snippet

Sponsor: Soonchunhyang University Hospital | Conditions: Benign Neoplasm of Stomach, Malignant Neoplasm of Stomach | NA | Status: COMPLETED